Cogent Biosciences, Inc. (COGT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-03

Key Insights

Karen Jean Ferrante, a director of Cogent Biosciences, Inc. (COGT), was granted 686 stock options on April 1, 2026 as part of her director compensation package.
The options have an exercise price of $35.24 and will expire on April 1, 2036, aligning the director's interests with those of shareholders.
This insider transaction suggests continued confidence in the company's future prospects and alignment of management and board incentives.

Want the newest filings?

This analysis covers the filing from 2026-04-03. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-31

Fairmount Funds Management LLC, a 10% owner of Cogent Biosciences, Inc. (COGT), converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of common stock on March 31, 2026.
Fairmount Healthcare Fund II LP, an entity affiliated with Fairmount Funds Management LLC, sold 7,000,000 shares of COGT common stock on March 31, 2026 at a price of $34.66 per share.
The reporting person, Fairmount Funds Management LLC, may be considered a director of COGT by deputization due to the fact that one of its managing members, Peter Harwin, serves on COGT's board of directors.

Filed: 2026-01-22

Fairmount Funds Management LLC, a director and 10% owner of Cogent Biosciences, Inc. (COGT), has reported the sale of 3,500,000 shares of the company's common stock at $36.4 per share.
The sale represents a substantial portion of Fairmount's stake in Cogent, reducing its beneficial ownership from a previously higher level.
This transaction could signal a shift in Fairmount's investment strategy or portfolio allocation, which investors may want to monitor going forward.

Filed: 2026-01-05

Karen Jean Ferrante, a director of Cogent Biosciences, Inc. (COGT), was granted 643 stock options on 01/01/2026 as part of her non-employee director compensation.
The options have an exercise price of $34.74 and will expire on 01/01/2036, indicating that Ferrante is incentivized to create long-term value for the company.
This insider transaction suggests that Ferrante, who is a director, has confidence in the company's future prospects and is aligning her interests with those of shareholders.

Filed: 2025-12-30

The reporting person, John Edward Robinson, who is the Chief Scientific Officer of Cogent Biosciences, Inc., sold 90,000 shares of the company's common stock on December 26, 2025 at a weighted average price of $38.74.
The reporting person still holds 140,002 shares of the company's common stock following the reported transaction, which includes previously reported shares of common stock underlying restricted stock units granted to the reporting person.
The sale of 90,000 shares by the Chief Scientific Officer may indicate a reduction in his confidence or commitment to the company's long-term prospects.

Filed: 2025-12-30

Jessica Sachs, the Chief Medical Officer of Cogent Biosciences, Inc., sold 82,642 shares of the company's common stock on December 26, 2025 at a weighted average price of $38.70 per share.
Sachs still holds 133,938 shares of Cogent Biosciences, indicating she maintains a substantial ownership stake in the company.
The sale of shares by Sachs, a key executive, could signal potential changes or uncertainty within the company, which investors should monitor closely.

Filed: 2025-12-30

The reporting person, John L. Green, who is the Chief Financial Officer of Cogent Biosciences, Inc., sold 77,000 shares of the company's common stock at a weighted average price of $38.68 per share.
This transaction reduces Green's direct beneficial ownership of Cogent Biosciences' common stock to 131,834 shares, indicating a reduction in his stake in the company.
The sale of shares by the CFO could suggest reduced confidence in the company's future performance or a need to raise personal funds, which may be viewed as a negative signal by investors.

Filed: 2025-12-30

Insider Evan Kearns, the Chief Legal Officer, sold 65,000 shares of Cogent Biosciences, Inc. (COGT) on 2025-12-26 at a weighted average price of $38.70 per share.
The sale represents a significant reduction in Kearns' beneficial ownership of COGT shares, which now stands at 109,398 shares.
Insider selling can sometimes signal a lack of confidence in the company's future prospects, so investors may want to monitor any further changes in Kearns' or other insiders' holdings.

Other reports for Cogent Biosciences, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.